InnovAge Holding (INNV) Aperçu de l'action
InnovAge Holding Corp. gère et fournit une gamme de services médicaux et auxiliaires aux personnes âgées qui ont besoin de soins et de soutien pour vivre de manière indépendante dans ses maisons et ses communautés. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour INNV à partir de nos contrôles de risques.
INNV Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
InnovAge Holding Corp. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$11.99 |
| Plus haut sur 52 semaines | US$12.64 |
| Plus bas sur 52 semaines | US$3.13 |
| Bêta | 0.35 |
| Variation sur 1 mois | 66.53% |
| Variation sur 3 mois | 57.56% |
| Variation sur 1 an | 168.83% |
| Variation sur 3 ans | 79.49% |
| Variation sur 5 ans | -41.51% |
| Évolution depuis l'introduction en bourse | -50.45% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 19
INNV: Unchanged Assumptions And 2026 Guidance Will Restrain Stock Upside
Analysts have kept their fair value estimate for InnovAge Holding steady at $7.00 per share, reflecting largely unchanged assumptions for the discount rate, revenue growth, profit margin, and future P/E in their updated price target work. What’s in the News for InnovAge Holding InnovAge Holding issued updated corporate guidance for fiscal 2026, providing investors with a more detailed view of expected performance.Mise à jour du récit • Jun 05
INNV: 2026 Guidance And Margin Outlook Will Shape Balanced Risk Reward
Analysts have kept their price target on InnovAge Holding steady at $7.00, pointing to slightly lower modeled revenue growth, a higher projected profit margin, and a modestly reduced future P/E assumption as key drivers of the updated view. What's in the News InnovAge Holding raised earnings guidance for fiscal 2026, with total revenues now expected in a range of US$950 million to US$975 million.Mise à jour du récit • May 16
INNV: Updated Modeling And 2026 Guidance Will Shape Balanced Risk Reward Outlook
Analysts have raised their price target on InnovAge Holding to $7 from $5, reflecting updated modeling related to fair value, discount rate, growth expectations, profit margins, and future P/E assumptions. Analyst Commentary JPMorgan raised its price target on InnovAge Holding to US$7 from US$5 after updating its model, while maintaining an Underweight rating on the stock.Recent updates
Mise à jour du récit • Jun 19
INNV: Unchanged Assumptions And 2026 Guidance Will Restrain Stock Upside
Analysts have kept their fair value estimate for InnovAge Holding steady at $7.00 per share, reflecting largely unchanged assumptions for the discount rate, revenue growth, profit margin, and future P/E in their updated price target work. What’s in the News for InnovAge Holding InnovAge Holding issued updated corporate guidance for fiscal 2026, providing investors with a more detailed view of expected performance.Mise à jour du récit • Jun 05
INNV: 2026 Guidance And Margin Outlook Will Shape Balanced Risk Reward
Analysts have kept their price target on InnovAge Holding steady at $7.00, pointing to slightly lower modeled revenue growth, a higher projected profit margin, and a modestly reduced future P/E assumption as key drivers of the updated view. What's in the News InnovAge Holding raised earnings guidance for fiscal 2026, with total revenues now expected in a range of US$950 million to US$975 million.Mise à jour du récit • May 16
INNV: Updated Modeling And 2026 Guidance Will Shape Balanced Risk Reward Outlook
Analysts have raised their price target on InnovAge Holding to $7 from $5, reflecting updated modeling related to fair value, discount rate, growth expectations, profit margins, and future P/E assumptions. Analyst Commentary JPMorgan raised its price target on InnovAge Holding to US$7 from US$5 after updating its model, while maintaining an Underweight rating on the stock.Mise à jour du récit • Apr 20
INNV: Updated Modeling And 2026 Guidance Will Likely Limit Future Share Upside
Analysts raised their price target on InnovAge Holding to $7 from $5, citing updated company modeling as the key driver of the change. Analyst Commentary The move to a US$7 price target signals that at least one major firm sees enough change in the underlying assumptions to justify a higher valuation for InnovAge Holding, even while keeping a cautious stance on the stock.Mise à jour du récit • Apr 05
INNV: Updated Modeling And 2026 Guidance Will Likely Temper Upside Expectations
Analysts have raised their price target on InnovAge Holding to $7 from $5, reflecting updated modeling assumptions that incorporate refined views on fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary JPMorgan's updated price target signals a fresh look at InnovAge Holding's valuation framework, even as the firm maintains an Underweight stance.Mise à jour du récit • Mar 22
INNV: Raised Outlook And Model Assumptions Will Likely Prove Overly Optimistic
Analysts have lifted their price target on InnovAge Holding to $7 from $5, reflecting updated models that refine assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts view the lift in the price target to $7 as a sign that updated assumptions on fair value and discount rates support a higher implied equity valuation.Mise à jour du récit • Mar 08
INNV: Raised Outlook And P/E Assumptions Will Likely Prove Overly Optimistic
Analysts have lifted their price target on InnovAge Holding to $7 from $5, reflecting updated modeling assumptions around fair value, discount rate, revenue growth, profit margin and future P/E that collectively support a modestly higher valuation framework. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a US$7 price target as recognition that updated fair value work supports a somewhat higher valuation range than before.Seeking Alpha • Feb 23
InnovAge: The Headwinds Are Priced In, The Growth May Not Be
Summary InnovAge Holding Corp. delivers strong operational execution, driving significant revenue and margin expansion through its PACE model for elderly care. INNV’s revenue rose 14.7% year-over-year, fueled by participant growth and capitation rate adjustments across established centers. Disciplined cost management and SG&A reductions have expanded center-level contribution margin to 22% and adjusted EBITDA margin to 9.2%. Despite Medicaid eligibility headwinds, INNV’s improved processes and in-house pharmacy transition support a bullish outlook on sustainability and leverage. Read the full article on Seeking AlphaMise à jour du récit • Feb 21
INNV: Future Margin Assumptions Will Likely Prove Overly Optimistic
Analysts have revised their price target on InnovAge Holding, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Together, these factors result in a new target of $7.00, up from $5.00.Article d’analyse • Feb 06
Earnings Beat: InnovAge Holding Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
InnovAge Holding Corp. ( NASDAQ:INNV ) investors will be delighted, with the company turning in some strong numbers...Article d’analyse • Jan 17
InnovAge Holding Corp.'s (NASDAQ:INNV) Price In Tune With Revenues
It's not a stretch to say that InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 0.9x right...Article d’analyse • Dec 13
InnovAge Holding (NASDAQ:INNV) Might Be Having Difficulty Using Its Capital Effectively
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Article d’analyse • Nov 07
InnovAge Holding Corp. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, InnovAge Holding Corp. ( NASDAQ:INNV ) just kicked off its latest quarterly results with some very...Article d’analyse • Nov 03
Is InnovAge Holding (NASDAQ:INNV) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Sep 10
Improved Revenues Required Before InnovAge Holding Corp. (NASDAQ:INNV) Stock's 32% Jump Looks Justified
InnovAge Holding Corp. ( NASDAQ:INNV ) shareholders would be excited to see that the share price has had a great month...Article d’analyse • Jul 08
Health Check: How Prudently Does InnovAge Holding (NASDAQ:INNV) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Nouveau récit • May 29
Expanding US Senior Care Integration Will Drive Healthcare Transformation
Enrollment growth and efficient geographic expansion are positioning the company for sustained revenue gains and scalable growth.Article d’analyse • May 09
After Leaping 36% InnovAge Holding Corp. (NASDAQ:INNV) Shares Are Not Flying Under The Radar
InnovAge Holding Corp. ( NASDAQ:INNV ) shares have had a really impressive month, gaining 36% after a shaky period...Article d’analyse • Apr 09
Is InnovAge Holding (NASDAQ:INNV) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Article d’analyse • Feb 06
Investors Aren't Entirely Convinced By InnovAge Holding Corp.'s (NASDAQ:INNV) Revenues
InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 0.6x may look like a pretty appealing...Article d’analyse • Nov 07
Investors Aren't Entirely Convinced By InnovAge Holding Corp.'s (NASDAQ:INNV) Revenues
It's not a stretch to say that InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 1.1x seems...Article d’analyse • Aug 20
Is InnovAge Holding (NASDAQ:INNV) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Jun 28
InnovAge Holding Corp.'s (NASDAQ:INNV) Shares Leap 30% Yet They're Still Not Telling The Full Story
InnovAge Holding Corp. ( NASDAQ:INNV ) shares have had a really impressive month, gaining 30% after a shaky period...Article d’analyse • May 07
Sentiment Still Eluding InnovAge Holding Corp. (NASDAQ:INNV)
It's not a stretch to say that InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 0.8x right...Article d’analyse • Mar 15
InnovAge Holding (NASDAQ:INNV) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Jan 06
Market Still Lacking Some Conviction On InnovAge Holding Corp. (NASDAQ:INNV)
There wouldn't be many who think InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 1.1x is...Rendement pour les actionnaires
| INNV | US Healthcare | US Marché | |
|---|---|---|---|
| 7D | 11.1% | 2.0% | 1.6% |
| 1Y | 168.8% | 28.7% | 18.6% |
Rendement vs Industrie: INNV a dépassé le secteur US Healthcare qui a rapporté 28.7 % au cours de l'année écoulée.
Rendement vs marché: INNV a dépassé le marché US qui a rapporté 18.6 % au cours de l'année écoulée.
Volatilité des prix
| INNV volatility | |
|---|---|
| INNV Average Weekly Movement | 7.1% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: INNV n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de INNV ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1989 | 2,440 | Patrick Blair | www.innovage.com |
InnovAge Holding Corp. gère et fournit une gamme de services médicaux et auxiliaires aux personnes âgées qui ont besoin de soins et de soutien pour vivre de manière indépendante dans leurs foyers et leurs communautés. Elle gère ses activités dans le cadre du programme PACE (Program of All-Inclusive Care for the Elderly). La société propose également des services de soins à domicile (soins qualifiés, non qualifiés et personnels), des services en centre (soins primaires, kinésithérapie, ergothérapie, orthophonie, services dentaires, services de santé mentale et psychiatriques, repas et activités), le transport vers et depuis le centre PACE et les rendez-vous médicaux avec des tiers, ainsi que la gestion des soins.
InnovAge Holding Corp. Résumé des fondamentaux
| INNV statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$1.63b |
| Bénéfices(TTM) | -US$11.61m |
| Recettes(TTM) | US$949.17m |
1.7x
Ratio P/S-140.2x
Ratio P/ELe site INNV est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| INNV compte de résultat (TTM) | |
|---|---|
| Recettes | US$949.17m |
| Coût des recettes | US$300.41m |
| Marge brute | US$648.76m |
| Autres dépenses | US$660.37m |
| Les revenus | -US$11.61m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.086 |
| Marge brute | 68.35% |
| Marge bénéficiaire nette | -1.22% |
| Ratio dettes/capitaux propres | 22.4% |
Quelles ont été les performances à long terme de INNV?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/04 20:39 |
| Cours de l'action en fin de journée | 2026/07/02 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/06/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
InnovAge Holding Corp. est couverte par 14 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Steven Valiquette | Barclays |
| Sarah James | Barclays |